Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 10, 2026, 8:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2497–2520 of 21,042 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: ONE Clear all

Conditions: Injury in the Home
Interventions: Injury Prevention Measures; Other
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 6 Months to 36 Months
Enrollment: 520 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2012 – 2017
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Arterial Calcification, CD73 Deficiency
Interventions: Etidronate, MRI Scan; Drug · Device
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 80 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2021
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Primary Biliary Cholangitis
Interventions: Seladelpar 10 mg, Placebo; Drug
Lead sponsor: Gilead Sciences; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 43
States / cities: Chandler, Arizona • Pasadena, California • Sacramento, California + 32 more

Conditions: Herpes Zoster, Herpes Zoster Vaccine
Interventions: Herpes Zoster vaccine GSK 1437173A, Licensed pneumococcal polysaccharide conjugate vaccine (23-valent, adsorbed), Pneumovax 23™; Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 50 Years and older
Enrollment: 865 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2016
U.S. locations: 3
States / cities: Golden, Colorado • Wichita, Kansas • Columbia, Maryland

Conditions: DIABETIC MACULAR EDEMA
Interventions: Triamcinolone acetonide, laser; Drug · Procedure
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Overweight and Obesity, Adiposity, Nutrient; Excess, Physical Activity
Interventions: Nutrition and Physical Activity Intervention, English for Second Language Intervention; Behavioral · Other
Lead sponsor: University of Miami; Other
Eligibility: 3 Years to 50 Years
Enrollment: 578 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Hypertension
Interventions: Heart Health and Nutrition for Life (HHNL), Self-Measured Blood Pressure; Behavioral
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years to 84 Years
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Peripheral Vascular Disease, Intermittent Claudication, Peripheral Arterial Disease
Interventions: Levocarnitine tartrate, cilostazol; Dietary Supplement · Drug
Lead sponsor: Colorado Prevention Center; Other
Eligibility: 40 Years and older
Enrollment: 164 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 24
States / cities: Phoenix, Arizona • Little Rock, Arkansas • Palo Alto, California + 18 more

Conditions: Psoriasis, Plaque Psoriasis
Interventions: MK-0873 2% Cream, MK-0873 vehicle (placebo) Cream, Calcitriol Cream; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Fort Myers, Florida • Miramar, Florida

Conditions: Neonatal Jaundice
Interventions: Picterus Jaundice Pro (JP); Device
Lead sponsor: Picterus AS; Industry
Eligibility: 1 Day to 14 Days
Enrollment: 250 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Heart Diseases, Cardiovascular Diseases
Interventions: Dr. Dean Ornish Program for Reversing Heart Disease; Behavioral
Lead sponsor: Windber Research Institute; Other
Eligibility: 21 Years and older
Enrollment: 422 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2009
U.S. locations: 1
States / cities: Windber, Pennsylvania

Conditions: Arthritis, Femoroacetabular Impingement, Osteochondritis Dissecans, Hip Fractures, Ankle Fractures, Tibial Fractures
Interventions: Decision tool, Standard treatment information; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 2,310 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Healthy
Interventions: OEA supplement; Dietary Supplement
Lead sponsor: Nicole Stevens, PhD; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Pleasant Grove, Utah

Conditions: Sickle Cell Disease
Interventions: Collaborative Care Model, Promoting Resilience in Stress Management; Behavioral
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 8 Years to 25 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Epilepsy
Interventions: Photobiomodulation; Other
Lead sponsor: Cynthia Kerson; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: North Miami, Florida • Cincinnati, Ohio • Warren, Ohio + 1 more

Conditions: Opiate Dependence, Substance-related Disorders, Opioid-related Disorders
Interventions: Standard Medical Management (SMM) of Prescription Opiate Abuse, Enhanced Medical Management (EMM) of Prescription Opiate Abuse; Behavioral
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years and older
Enrollment: 653 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2013
U.S. locations: 12
States / cities: Los Angeles, California • San Francisco, California • Lawrenceburg, Indiana + 8 more

Conditions: GM2 Gangliosidosis, Tay-Sachs Disease, Sandhoff Disease
Interventions: IB1001; Drug
Lead sponsor: IntraBio Inc; Industry
Eligibility: 6 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 3
States / cities: Los Angeles, California • Rochester, Minnesota • New York, New York

Conditions: Smoking Cessation, Weight Gain
Interventions: Exenatide 2 milligram (mg) Injection, Placebo, Nicotine patch, Smoking Cessation Counseling; Drug · Behavioral
Lead sponsor: The University of Texas Health Science Center, Houston; Other
Eligibility: 18 Years to 75 Years
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2026
U.S. locations: 2
States / cities: Houston, Texas

Conditions: Chronic Myelogenous Leukemia, Acute Myelogenous Leukemia, Myelodysplastic Syndrome, Acute Lymphocytic Leukemia, Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Myelofibrosis, CMML, Multiple Myeloma
Interventions: Fludarabine, Melphalan, Cyclophosphamide, peripheral blood stem cell transplant; Drug · Procedure
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 18 Years to 75 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Fertility Preservation
Interventions: Oophorectomy; Procedure
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 0 Years to 42 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Obesity, Insulin Resistance
Interventions: Insulin, NG-monomethyl-L-arginine; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 50 Years
Enrollment: 33 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2016
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Differentiated Thyroid Cancer
Interventions: Everolimus, Sorafenib; Drug
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Vascular Diseases
Interventions: Phenylephrine, Dexmedetomidine, Clevidipine, tetanic stimulus, Increased venous pressure, Calcium Chloride; Drug · Other
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Vision Loss Partial, Vision; Loss, Both Eyes, Hemianopia Homonymous, Hemianopia, Quadrantanopia, Stroke, Ischemic, Stroke - Occipital Infarction, Cortical Blindness
Interventions: Training in the Blind Field; Device
Lead sponsor: University of Rochester; Other
Eligibility: 21 Years to 80 Years
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2032
U.S. locations: 1
States / cities: Rochester, New York

Search by objective public record fields.

Healthy Homes Healthy Children (H3C)

Etidronate for Arterial Calcifications Due to Deficiency in CD73 (ACDC)

Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC)

Study to Evaluate Immunogenicity and Safety Study of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A When Co-administered With Pneumovax 23™ in Adults Aged 50 Years and Older

Triamcinolone vs. Laser for Diabetic Macular Edema

Healthy Mothers-Healthy Children Nutrition

WEAVE NM: Heart Health and Nutrition for Life

Evaluation of Cilostazol in Combination With L-Carnitine

A Study to Evaluate and Compare the Efficacy and Pharmacokinetics of MK-0873 for the Treatment of Plaque Psoriasis (MK-0873-022)

Evaluation of a Smartphone-based Screening Tool (Picterus JP) for Neonatal Jaundice (Chicago)

Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal

Conjoint Analysis of Patient Preferences in Joint Interventions

Metabolic and Epigenetic Impact of FAAH Inhibitors and OEA

Promoting Resilience Among Adolescents and Young Adults With Sickle Cell Disease

An Examination of Whether Infrared Light Therapy Can Reduce Stress in People With Epilepsy

Prescription Opioid Addiction Treatment Study (POATS)

N-Acetyl-L-Leucine for GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease)

Exenatide for Smoking Cessation and Prevention of Weight Gain

Reduced Intensity Conditioning Transplant Using Haploidentical Donors

Ovarian Tissue Cryopreservation for Fertility Preservation in Girls and Women

Plasma Triglyceride Extraction by The Muscle

Study of Everolimus and Sorafenib in Patients With Advanced Thyroid Cancer Who Progressed on Sorafenib Alone

Effect of Changing Physiological Conditions on Myogenic Oscillations: Pilot Study

Effect of Visual Retraining After Stroke